Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
The Food and Drug Administration Aug. 16 announced the availability of a draft guidance to aid medical device manufacturers when the agency orders Section 522 postmarket surveillance studies.
Comments on the guidance, entitled “Procedures for Handling Section 522 Postmarket Surveillance Studies,” are due Nov. 14, according to the Federal Register notice (76 Fed. Reg. 50740).
Postmarket surveillance under Section 522 of the Federal Food, Drug, and Cosmetic Act is one means by which FDA can obtain additional safety and/or effectiveness data for a device after it has been cleared through the 510(k) premarket process or approved through the premarket approval application (PMA), humanitarian device exemption (HDE), or product development plan (PDP) process, when it is necessary to protect the public health.
Such surveillance is not a substitute for getting the necessary premarket information to support 510(k) clearance or PMA, HDE, or PDP approval.
Section 522 authorizes FDA to require postmarket surveillance in any of the following instances: a class II (moderate risk) or class III (highest risk) device for which failure of the device would be reasonably likely to have a serious adverse health consequence; a class II or class III device expected to have significant use in pediatric populations; or a class II or class III device intended to be a life-sustaining or life-supporting device used outside of a user facility.
According to FDA, the guidance document is intended to assist device manufacturers subject to a Section 522 postmarket surveillance order by providing an overview of the section, procedural information on how to fulfill Section 522 obligations, and recommendations on the format, content, and review of study submissions.
The guidance updates one that was issued on the same subject in 2006. According to FDA, substantive additions to the 2006 version of this guidance document include:
• guidance regarding the pediatric criterion added by Section 307 of the FDA Amendments Act of 2007;
• recommendations for the content of postmarket surveillance study submissions, consistent with previous FDA requests;
• descriptions of study status categories that more precisely indicate study progress and the adequacy of the data; and
• updated procedures based on the transfer of the program area to Division of Epidemiology (DEPI), Office of Surveillance and Biometrics (OSB).
The draft guidance is at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm268064.htm .
The Federal Register notice is at http://www.gpo.gov/fdsys/pkg/FR-2011-08-16/pdf/2011-20727.pdf .
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)